Related Experiment Video
Updated: Jan 9, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Two-Stage Drop-the-Losers Design for the Selection of Effective Treatments and Estimating Their Average Worth
Yogesh Katariya1, Neeraj Misra1
1Department of Mathematics and Statistics, Indian Institute of Technology Kanpur, Kanpur, India.
Abstract:
In multi-arm clinical trials, several new treatments are often evaluated concurrently to identify the best and confirm their superiority over a control. In this paper, we propose a framework that introduces an intermediate stage aimed at assessing the collective efficacy of treatments retained after initial screening. Estimating the average effect of the selected treatments provides an interpretable measure of their collective potential and serves as a data-driven criterion for deciding whether to continue or terminate the trial. Consider experimental treatments whose effects are described by independent Gaussian responses with unknown means and a common variance. For the purpose of selecting the effective treatments (drugs) and estimating their average worth, we employ a two-stage drop-the-losers design (DLD). To get an idea about the structure of an optimal estimator, we first assume that the common variance is known. In the first stage of the design, data is collected to select a subset of experimental treatments so that the probability of including the best treatment is at least a prespecified level . This selection rule ensures that inferior treatments are eliminated while maintaining a minimum confidence that the best treatment remains among those advanced. Given this requirement, the design either advances all selected treatments to the next stage or stops for futility. The treatment(s) selected in the subset then proceed to the second stage for estimating their collective effectiveness through point estimation of their average worth, defined as the arithmetic average of their mean effects. Since the bias of estimators is crucial in clinical studies, we derive the uniformly minimum variance conditionally unbiased estimator (UMVCUE) of the worth of the selected treatments, conditioned on the indices of treatments selected at the first stage. The mean squared error and bias performances of the UMVCUE are compared with the naive estimator (maximum likelihood estimator) via a simulation study. For the unknown variance scenario, we propose a plug-in estimator based on the structure of the UMVCUE derived for the known variance case and study its performance through simulations. A real-life data example is also provided to illustrate an application of our findings.
Insights
This study introduces a two-stage clinical trial framework to assess multiple experimental treatments. It uses a drop-the-losers design to select promising therapies and estimate their collective effect, improving decision-making in drug development.
Area of Science:
- Clinical Trial Design and Methodology
- Statistical Inference in Medical Research
Background:
- Multi-arm clinical trials often evaluate numerous treatments simultaneously.
- Identifying superior treatments and making informed decisions on trial continuation is challenging.
Purpose of the Study:
- To propose a novel two-stage framework for multi-arm clinical trials.
- To introduce an intermediate stage for assessing the collective efficacy of selected treatments.
- To provide a data-driven criterion for trial termination or continuation.
Main Methods:
- Utilized a two-stage drop-the-losers design (DLD) for selecting effective treatments.
- Assumed independent Gaussian responses with unknown means and common variance.
- Derived the uniformly minimum variance conditionally unbiased estimator (UMVCUE) for treatment worth.
Main Results:
- The first stage selects a subset of treatments ensuring a high probability of retaining the best one.
- The second stage estimates the collective effectiveness using the UMVCUE.
- Simulations demonstrate superior performance of UMVCUE compared to the naive estimator.
Conclusions:
- The proposed framework offers an interpretable measure of collective treatment potential.
- The DLD with UMVCUE provides a robust method for multi-arm clinical trial analysis.
- The approach facilitates efficient decision-making regarding trial continuation or termination.
More Related Videos
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
20:24Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
Published on: January 31, 2014
Related Concept Videos
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Randomized Experiments
Simple randomization
Simple...
Group Design
Dosage Regimens: Designs and Approaches